Hossein Heidari kaydan

Prof. Dr. Hossein Heidari kaydan


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2024 in Jundishapur Journal of Natural Pharmaceutical Products
Verified
Journal Article
Open access
PDF file
HKHossein Heidari kaydan
Hossein Heidari kaydan
BMBehzad Sharif Makhmlzadeh
Behzad Sharif Makhmlzadeh
MFMostafa Feghhi
Mostafa Feghhi
ARAnahita Rezaei
Anahita Rezaei
FBFarid Bagheri
Farid Bagheri
ASAnayatollah Salimi
Anayatollah Salimi
Background: Limitations in drug penetration are overcome by nanotechnology, particularly liposomes, which enhance targeted administration of ocular medications. Liposomes can augment the therapeutic effects of curcumin, a natural compound with positive impacts on the retina. Treatments for eye diseases can also benefit from the antibacterial properties of ozonated oil liposomes. Objectives: This study aims to develop and evaluate ozonated liposomes loaded with curcumin for ocular drug delivery applications, specifically targeting diabetic retinopathy (DR). Methods: Liposomal nanoparticles were prepared using thin-film hydration, incorporating phospholipids, lecithin, cholesterol, ozonated oil, and curcumin. We assessed physicochemical properties including particle size, zeta potential, encapsulation efficiency (EE), and morphology. Drug release profiles and stability studies were also conducted. Results: The optimized liposomes showed a particle size of 84.77 nm, a zeta potential of -16.8 mV, and an EE of 94.73%. The formulation exhibited sustained curcumin release over 24 hours, reaching 82.09% cumulative release. Stability studies indicated minimal changes in key parameters over three months at room temperature. Conclusions: The developed ozonated liposomal formulation demonstrates promising characteristics for curcumin delivery, potentially enhancing its therapeutic efficacy in ocular applications, particularly for DR.

18 July 2026 in Jundishapur Journal of Natural Pharmaceutical Products
Verified
Journal Article
Open access
PDF file
EMEskandar Moghimipour
Eskandar Moghimipour
ASAnayatollah Salimi
Anayatollah Salimi
SHSomayeh Handali
Somayeh Handali
DDDian Dayer
Dian Dayer
AMAlireza Malayeri
Alireza Malayeri
AJAli Javadiyeh
Ali Javadiyeh
Background: Nanostructured lipid carriers (NLCs) are promising vehicles for the topical delivery of poorly permeable drugs such as methotrexate (MTX). In conventional NLCs, the liquid lipid serves primarily as a structural component, whereas incorporating a bioactive natural liquid lipid may provide additional formulation benefits for the resulting carrier. Objectives: This study aimed to design and physicochemically characterize MTX-loaded NLCs using eicosapentaenoic acid (EPA), a natural omega-3 fatty acid, as a bioactive liquid lipid, and to identify an optimal formulation through a systematic two-level formulation design. Methods: Eight formulations were prepared by hot emulsification followed by sonication, with varying amounts of solid lipid (stearic acid), liquid lipid (EPA), and surfactant (soya lecithin). The MTX assay was validated by reversed-phase high-performance liquid chromatography (HPLC) for linearity, limit of detection (LOD), limit of quantification (LOQ), precision, selectivity, and matrix-matched recovery. The formulations were characterized in terms of particle size, polydispersity index (PDI), zeta potential, entrapment efficiency (EE%), drug loading (DL%), and in vitro release. The release kinetics of the optimal formulation were evaluated using four models (zero-order, first-order, Higuchi, and Korsmeyer-Peppas), and physical stability was monitored for three months. Results: The HPLC method was linear over 1 - 20 µg/mL (R2 = 0.9981), with LOD and LOQ of 1.56 and 4.72 µg/mL, respectively, and precision of RSD ≤ 2%. Particle size ranged from 88.92 to 160.7 nm, and PDI ranged from 0.252 to 0.405. The optimal formulation (F5; stearic acid 200 mg, EPA 20 mg, lecithin 40 mg) showed a particle size of 88.92 nm, a PDI of 0.284, a zeta potential of ‒18.5 mV, an EE% of 88.40%, and a DL% of 7.89%. Its 24 h cumulative release reached 88.03%; among the tested models, the release best fit the Korsmeyer-Peppas (R2 = 0.987; n = 1.12) and first-order (R2 = 0.977) models, indicating a coupled diffusion–relaxation mechanism. All formulations remained physically stable over three months. Conclusions: EPA can serve as a bioactive liquid lipid in NLCs, producing nanoscale carriers with high entrapment, adequate drug loading, and sustained release. These findings provide a robust physicochemical basis for topical MTX carriers; however, biological and skin-delivery validation is required before any therapeutic benefit of EPA can be claimed.

15 September 2026 in Jundishapur Journal of Natural Pharmaceutical Products
Verified
Journal Article
Open access
PDF file
FGFereshteh Golfakhrabadi
Fereshteh Golfakhrabadi
HKHossein Heidari kaydan
Hossein Heidari kaydan
MSMaryam Shirani
Maryam Shirani
BRBehjat Rezaee
Behjat Rezaee
NANegar Ashoori
Negar Ashoori
ASAnayatollah Salimi
Anayatollah Salimi
Background: Oral candidiasis is a common opportunistic mycosis, and its management is complicated by the increasing prevalence of non-albicans Candida species and by azole resistance, whereas conventional chlorhexidine rinses are limited by tooth staining and dysgeusia. Flowers of Punica granatum var. pleniflora and leaves of Myrtus communis are polyphenol-rich botanicals with documented antifungal potential, providing a rational basis for a combined formulation. Objectives: We formulated a polyherbal mouthwash from the two extracts and evaluated its physicochemical properties and anticandidal activity against three clinically relevant Candida species, using a marketed herbal rinse as the comparator. Methods: Hydroethanolic extracts were prepared by maceration in 70% ethanol. Total phenolic content (TPC) was quantified using the Folin–Ciocalteu assay, with tannic acid as the standard. Minimum inhibitory and fungicidal concentrations (MIC/MFC) were determined by broth macrodilution against C. albicans (PTCC 5027), C. krusei (PTCC 5295), and C. parapsilosis. Mouthwashes containing 1%, 2.5%, and 5% total extract were evaluated for pH and Brookfield viscosity, and zones of inhibition (ZOI) were measured using the agar well diffusion method (n = 3) alongside a vehicle control and the commercial rinse Persica™. Data were analysed using two-way ANOVA with Tukey HSD. Results: TPC reached 4626.00 ± 42.50 and 3287.00 ± 31.20 µg tannic-acid equivalents/g for pomegranate flower and myrtle leaf extracts, respectively; MIC and MFC were 50 and 100 mg/mL, respectively, for both extracts across all strains, indicating that the crude extracts were fungicidal (MFC/MIC = 2), whereas the finished 5% rinse delivers approximately 50 mg/mL of extract, that is, a concentration at the inhibitory (MIC) level rather than the fungicidal level. The 5% formulation (F-D) was near-neutral (pH 6.52 ± 0.02) and produced the largest inhibition among formulations (23.00 ± 0.82 mm against C. parapsilosis), with no significant difference compared with Persica™ against this species (P = 0.412). Formulation was the principal source of variance in inhibition (F7,48 = 1046.40, P < 0.001, partial η2 = 0.99). Conclusions: The lead 5% polyherbal rinse combined a near-neutral pH maintained above the critical enamel demineralisation threshold with marked anticandidal activity, and its effect against C. parapsilosis was comparable to that of a marketed herbal comparator. These findings support the further development of this rinse as an adjunctive oral antifungal, pending cytotoxicity, stability, and clinical validation.

26 July 2026 in Jundishapur Journal of Natural Pharmaceutical Products
Verified
Journal Article
Open access
PDF file
ASAnayatollah Salimi
Anayatollah Salimi
MKMasoud Ali Karami
Masoud Ali Karami
EHEhsan Afshari Hosseinpur
Ehsan Afshari Hosseinpur
YSYasaman Salimi
Yasaman Salimi
HKHossein Heidari kaydan
Hossein Heidari kaydan
ANAmin Noori
Amin Noori
Background: Cetirizine is a zwitterionic, second-generation H1-antihistamine widely used to treat allergic rhinitis and chronic urticaria. Although it has high oral bioavailability (> 70%), its use is limited by dose-related sedation and interindividual variability, supporting investigation of alternative topical and transdermal delivery approaches. Objectives: This study aimed to formulate, optimize, and evaluate cetirizine microemulsions containing oleic acid and Transcutol P as natural-origin penetration enhancers, using a two-level full-factorial design, and to elucidate the mechanisms underlying enhanced ex vivo skin permeation. Methods: Eight microemulsions were prepared using oleic acid and Transcutol P as the oil phase, Tween 80 and Span 20 as surfactants, and propylene glycol as a cosurfactant; each contained 1% (w/w) cetirizine. Oil content (5% and 50%), water content (5% and 10%), and the surfactant/cosurfactant ratio (1:1 and 3:1) were varied. The formulations were characterized for droplet size, polydispersity index, viscosity, pH, physical stability, in vitro release, and ex vivo rat-skin permeation. Factorial analysis was used to evaluate effects on steady-state flux (Jss). Results: Droplet sizes ranged from 14.94 to 46.15 nm, with a polydispersity index < 0.5. The optimal formulation, ME-CET-6 (5% oil, 10% water, S/C 1:1), yielded the highest flux (Jss = 0.0431 ± 0.003 mg·cm-2·h-1; ERflux = 5.42), representing an approximately 4.6-fold increase compared with the aqueous control. Factorial analysis identified oil content as the primary negative determinant of flux (P = 0.001), followed by the S/C ratio (P = 0.015), whereas water content was not significant (P = 0.119). Corrected diffusion enhancement ratios exceeded 1 for all microemulsions, indicating that improved diffusivity and partitioning jointly contributed to permeation enhancement. Conclusions: Cetirizine microemulsions containing oleic acid and Transcutol P markedly enhance transdermal flux through combined increases in drug diffusivity and partitioning. These systems are promising candidates for further in vivo pharmacokinetic and skin irritation evaluation.

29 July 2026 in Jundishapur Journal of Natural Pharmaceutical Products
Verified
Journal Article
Open access
PDF file
ASAnayatollah Salimi
Anayatollah Salimi
BZBehzad Sharif makhmal zadeh
Behzad Sharif makhmal zadeh
HBHassan Binazir
Hassan Binazir
YSYasaman Salimi
Yasaman Salimi
SSSaeed Mohammad Soleymani
Saeed Mohammad Soleymani
HKHossein Heidari kaydan
Hossein Heidari kaydan
Background: Curcumin has potent anti-inflammatory and antioxidant activities relevant to inflammatory skin diseases; however, its dermal use is limited by its negligible aqueous solubility, instability, and the stratum corneum barrier. Objectives: This study screened phospholipid liposomes loaded exclusively with curcumin and quantified their permeation across excised rat skin, compared with a free-curcumin control. Methods: Four formulations were prepared by thin-film hydration according to a two-level full factorial design (22), varying cholesterol (10 and 20 mg) and lecithin (30 and 60 mg) at constant curcumin content. Particle size, polydispersity index (PDI), encapsulation efficiency (EE%), zeta potential, and morphology (scanning electron microscopy) were determined, and coded models were fitted by ordinary least squares with analysis of variance. Release was evaluated using mean squared error and the small-sample-corrected Akaike Information Criterion; permeation was assessed in Franz cells, and stability was assessed over six months at 4 and 25 °C (n = 3). Results: Size ranged from 113.3 nm with an SD of 13.6 nm (F4) to 181.7 nm with an SD of 2.5 nm (F2), with lecithin as the dominant factor and showing a significant cholesterol–lecithin interaction. EE% ranged from 89.41% to 91.30%, and PDI did not exceed 0.36. Zeta potential was moderately negative throughout (-15.75 to -18.58 mV) and was most negative for F4. Scanning electron microscopy confirmed spherical, uniform vesicles without drug crystallization. Release followed the Weibull model throughout. F4 produced the smallest vesicles, the highest release (94.87%), and the highest flux (Jₛₛ = 1.54 with an SD of 0.19 µg·cm-2·h-1), representing a 2.45-fold enhancement over the control, and retained 99.85% curcumin with an SD of 0.02% after 180 days at 4 °C, with only 3.1% vesicle growth. Conclusions: A compact 22 design clarified the respective roles of cholesterol and lecithin. F4 combined the smallest vesicles with the highest transdermal flux and excellent refrigerated stability, supporting phospholipid liposomes as rational topical carriers for curcumin.

3 August 2026 in Jundishapur Journal of Natural Pharmaceutical Products
Verified
Journal Article
Open access
PDF file
ASAnayatollah Salimi
Anayatollah Salimi
MEMohammad Sadegh Esmaeili
Mohammad Sadegh Esmaeili
ANAmin Noori
Amin Noori
SSSaeed Mohammad Soleymani
Saeed Mohammad Soleymani
ASArghavan Salimi
Arghavan Salimi
HKHossein Heidari kaydan
Hossein Heidari kaydan
Background: Curcumin is a polyphenolic natural product with well-documented anti-inflammatory and antioxidant activity; however, its use as a topical agent is constrained by aqueous insolubility, poor partitioning across the stratum corneum, and Biopharmaceutics Classification System (BCS) class IV behavior. Objectives: This study aimed to prepare, screen, and characterize curcumin-loaded microemulsions; to quantify their capacity to enhance delivery across excised rat skin relative to an aqueous suspension; and to select a lead candidate among the tested compositions. Methods: Eight microemulsions were prepared using oleic acid and Transcutol P (oil phase), Tween 80/Span 20 (surfactant), and propylene glycol (co-surfactant), according to a 23 full factorial design. The independent variables were total oil content (5% vs. 50% w/w), water-phase fraction (5% vs. 10% w/w), and the surfactant-to-co-surfactant (Smix) ratio (1:1 vs. 3:1). Droplet size, polydispersity index (PDI), viscosity, in vitro release, and ex vivo permeation through rat abdominal skin (Franz cells; barrier integrity verified) were evaluated. Effects were modeled using ordinary least-squares regression and tested by analysis of variance (ANOVA) against a pure-error term pooled from triplicate measurements; reduced models, confidence intervals, and lack-of-fit tests were used to evaluate the permeation responses. Results: The validated UV-spectrophotometric assay was linear (y = 68.019x − 0.0025; R2 = 0.9997), precise (relative standard deviation [RSD] < 2.5%), and accurate (recovery 96.58 - 105.64%), with a limit of detection (LOD) of 0.22 µg/mL and a limit of quantification (LOQ) of 0.68 µg/mL. Droplet size ranged from 34.0 ± 1.0 to 158.0 ± 2.0 nm. Oil content was the dominant factor affecting size, PDI, steady-state flux (Jss), and permeability (P < 0.0001 for size), whereas the Smix ratio governed the apparent diffusion coefficient (P = 0.037). Reduced models for flux and the diffusion coefficient showed no significant lack of fit (P = 0.529 and P = 0.598, respectively). The lead formulation F5 (5% oil, 5% water, Smix 3:1) exhibited a droplet size of 34.0 ± 1.0 nm, a PDI of 0.201 ± 0.004, a 24-h cumulative release of 94.95% (Higuchi kinetics, R2 = 0.9994, n = 0.417), a steady-state flux of 6.16 ± 0.60 µg/cm2/h versus 0.63 ± 0.10 µg/cm2/h for the aqueous comparator, and the shortest lag time (0.82 ± 0.36 h), reaching approximately 133 µg/cm2 of cumulative 24-h permeation versus approximately 11 µg/cm2 for the comparator. Enhancement ratios across the series ranged from 7.2 to 10.5, expressed as ex vivo screening ratios. Conclusions: The microemulsion platform improved curcumin release and skin permeation relative to an aqueous suspension. F5 was identified as the lead candidate among the eight compositions screened, rather than as a formal optimum, because a two-level design without center points cannot detect curvature. The aqueous suspension was a non-solubilized negative control, not a positive control, and formal sink conditions were not maintained at the 24-h endpoint; both points are addressed in the Limitations. F5 represents a promising vehicle for an ex vivo and in vitro proof-of-concept topical curcumin product, warranting subsequent in vivo safety evaluation, including formal skin irritation testing, and efficacy evaluation.